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SUMMARY
Numerous pain-producing (pronociceptive) receptors signal via phosphatidylinositol 4,5-
bisphosphate (PIP2) hydrolysis. However, it is currently unknown which lipid kinases generate
PIP2 in nociceptive dorsal root ganglia (DRG) neurons and if these kinases regulate
pronociceptive receptor signaling. Here, we found that phosphatidylinositol 4-phosphate 5 kinase
type 1C (PIP5K1C) is expressed at higher levels than any other PIP5K and, based on experiments
with Pip5k1c+/− mice, generates at least half of all PIP2 in DRG neurons. Additionally, Pip5k1c
haploinsufficiency reduces pronociceptive receptor signaling and TRPV1 sensitization in DRG
neurons as well as thermal and mechanical hypersensitivity in mouse models of chronic pain. We
identified a novel small molecule inhibitor of PIP5K1C (UNC3230) in a high-throughput screen.
UNC3230 lowered PIP2 levels in DRG neurons and attenuated hypersensitivity when administered
intrathecally or into the hindpaw. Our studies reveal that PIP5K1C regulates PIP2- dependent
nociceptive signaling and suggest that PIP5K1C is a novel therapeutic target for chronic pain.
INTRODUCTION
Tissue inflammation and nerve injury cause the release of a complex mix of chemicals that
sensitize nociceptive dorsal root ganglia (DRG) neurons and contribute to chronic pain
(Basbaum et al., 2009). These chemicals activate molecularly diverse pronociceptive
receptors found on DRG neurons and their axon terminals. While these receptors represent
attractive targets for analgesic drug development, efforts to block individual pronociceptive
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receptors have not yet produced effective treatments for chronic pain (Gold and Gebhart,
2010). This lack of efficacy could reflect the fact that multiple pronociceptive receptors are
activated in the setting of chronic pain.
One approach to treat pain that bypasses this receptor diversity is to target points where
different signaling pathways converge. Indeed, drugs that block signaling proteins that are
several steps downstream from receptor activation, including protein kinase Cε (PKCε) and
mitogen activated protein kinases (MAPKs), reduce nociceptive neuron sensitization,
thermal hyperalgesia and mechanical allodynia in animal models (Aley et al., 2001; Aley et
al., 2000; Cesare et al., 1999; Cheng and Ji, 2008; Dai et al., 2002; Ji et al., 2009; Ji et al.,
2002). However, drugs that inhibit PKCε or MAPKs have shown modest-to-no efficacy in
treating different pain conditions in humans (Anand et al., 2011; Cousins et al., 2013;
Ostenfeld et al., 2013; Tong et al., 2011). This limited efficacy does not mean that PKCε or
MAPK inhibitors cannot be used to treat pain, as drugs can show limited-to-no efficacy for a
number of reasons, including the drugs may not engage their molecular target in humans or
the drugs may lack efficacy in some pain conditions but not others.
Another convergence point, albeit one that has not been fully explored in the context of
treating pain, is immediately downstream of multiple pronociceptive receptors. Many
pronociceptive receptors, including Gq-coupled receptors, Gs-coupled receptors (via
EPAC), and receptor tyrosine kinases, initiate signaling upon phospholipase C (PLC)-
mediated hydrolysis of the lipid second messenger PIP2 (Hucho et al., 2005). PIP2
hydrolysis produces diacylglycerol (DAG) and inositol-1,4,5-trisphosphate (IP3), which
regulate nociceptive sensitization via multiple pathways, including PKCdependent
modulation of ion channels like TRPV1, MAPK activation, and IP3-mediated calcium influx
(Falkenburger et al., 2010; Gamper and Shapiro, 2007; Gold and Gebhart, 2010; Rohacs et
al., 2008; Tappe-Theodor et al., 2012). PIP2 thus sits at a convergence point for diverse
receptors and signaling pathways that promote and maintain nociceptive sensitization. In
light of this information, we reasoned that it might be possible to reduce signaling through
pronociceptive receptors and reduce pain sensitization by inhibiting the lipid kinase that
generates the majority of all PIP2 in DRG neurons.
Type 1 phosphatidylinositol 4-phosphate 5-kinases (Pip5k1s) generate PIP2 by
phosphorylating the 5 position on the inositol ring of phosphatidylinositol 4-phosphate
[PI(4)P]. There are three mammalian Pip5k1 genes (Pip5k1a, Pip5k1b and Pip5k1c)
(Ishihara et al., 1998). Of these, Pip5k1c (also known as Pip5k1γ) is highly expressed in the
brain (Wenk et al., 2001). PIP5K1C regulates receptor-mediated calcium signaling, actin
cytoskeletal dynamics, endocytosis, and exocytosis (Di Paolo et al., 2004; Legate et al.,
2012; Ling et al., 2002; Unoki et al., 2012; van den Bout and Divecha, 2009; Vasudevan et
al., 2009; Volpicelli-Daley et al., 2010; Wang et al., 2007; Wang et al., 2004; Xu et al.,
2010; Yu et al., 2011).
Previous studies examined the functions of Pip5k1c in the brain of knockout mice (Di Paolo
et al., 2004; Rodriguez et al., 2012; Volpicelli-Daley et al., 2010; White et al., 2013).
Homozygous (Pip5k1c−/−) knockout mice have ~50% less PIP2 in their brains and die
within 24 hours of birth due to impaired mobility and an inability to feed (Di Paolo et al.,
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2004; White et al., 2013). These data suggest a critical role for PIP5K1C in generating PIP2
in neurons and in nervous system development. In contrast, heterozygous (Pip5k1c+/−) mice
are viable, reproduce normally, have normal levels of PIP2 in the brain and showed no
phenotypes in an extensive battery of tests, including multiple tests of neurological function
(Di Paolo et al., 2004; White et al., 2013). The only phenotype observed thus far in
Pip5k1c+/− mice is high-frequency (>20 kHz) hearing loss (Rodriguez et al., 2012), a
phenotype ascribed to Pip5k1c haploinsufficiency in non-sensory cells of the auditory
system.
When we initiated our studies, it was unknown which enzymes generated PIP2 in
nociceptive DRG neurons or if these enzymes regulated nociception. Here, we report that
PIP5K1C is expressed in nearly all DRG neurons, generates at least half of all PIP2 in the
DRG and regulates nociceptive sensitization in response to diverse stimuli that cause pain.
Our studies are the first to validate PIP5K1C as an analgesic drug target and identify a
PIP5K1C inhibitor that attenuates pain in animal models.
RESULTS
PIP5K1C generates at least half of all PIP2 in DRG neurons
To determine which Pip5k1s were expressed in the DRG, we performed in situ hybridization
with probes for the three known mammalian Pip5k1 genes. We found that Pip5k1c was
expressed at higher levels in adult mouse DRG than the two other Pip5k1 genes and was
expressed in nearly all DRG neurons (Figure 1A–1C). PIP5K1C is also present in the brain
at higher levels than PIP5K1A and PIP5K1B (Akiba et al., 2002; Wenk et al., 2001).
Consistent with widespread expression in all DRG neurons, based on in situ hybridization,
Pip5k1c was expressed in virtually all peptidergic (96.7%; n=220 counted) and
nonpeptidergic (96.1%; n=210 counted) nociceptive neurons, marked by Calcitonin gene-
related peptide-alpha (Cgrp) and Prostatic acid phosphatase (Pap), respectively (Figure 1D
and 1E) (McCoy et al., 2013; Zylka et al., 2008). Using a recently developed antibody (Hara
et al., 2013), we found that PIP5K1C was present on the plasma membrane and in the
cytoplasm of most DRG neurons (Figure S1A–C). PIP5K1C was highly colocalized with
PAP (98.1%; n=2,672 counted), CGRP (97.5%; n=2,094 counted), and TRPV1 (92.2%;
n=1,915 counted), markers of nociceptive neurons (Figure S1D-L). Moreover, PIP5K1C
was expressed in human DRG at levels comparable to CGRP (Intensity values of 311 and
346, respectively, from Affymetrix GeneChip experiments).
We then quantified PIP5K1C protein and PIP2 levels in the DRG of wild-type (WT;
Pip5k1c+/+), Pip5k1c+/−, and Pip5k1c−/− embryonic (E17.5–E18.5) mice. We found that
PIP5K1C protein and PIP2 levels were reduced (by ~50%) in the DRG of Pip5k1c+/−
embryonic mice (Figure 1F–1H). No PIP5K1C protein was detectable in DRG from
Pip5k1c−/− embryonic mice, confirming complete gene knockout and that both antibodies
used in our study specifically recognized PIP5K1C (Figure 1F–1G). In addition, PIP2 was
reduced by ~70% in DRG from Pip5k1c−/− embryonic mice (Figure 1H).
Unlike Pip5k1−/− mice which die at birth, Pip5k1c+/− mice live into adulthood and
reproduce normally (Di Paolo et al., 2004). Therefore, we quantified PIP5K1C protein and
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PIP2 levels in the DRG from Pip5k1c+/− adult mice and WT littermate controls. PIP5K1C
protein was reduced by ~40% and PIP2 levels were reduced by ~50% in the DRG of
Pip5k1c+/− mice (Figure 1I–1K). In contrast, PIP2 was not reduced in spinal cord or brain
from adult Pip5k1c+/− mice (Figure 1K). Likewise, using a different quantification method,
PIP2 was not reduced in the brain of embryonic Pip5k1c+/− mice (Di Paolo et al., 2004;
Volpicelli-Daley et al., 2010). In addition, we used immunofluorescence staining to examine
PIP2 levels at the membrane of cultured DRG neurons taken from adult mice. Quantification
of the average perimeter (membrane) staining intensity in confocal images revealed that
membrane PIP2 levels were reduced by ~50% in small-to-medium diameter (≤ 27 μm)
neurons of Pip5k1c+/− mice compared to WT controls (Figure 1L and 1M). Taken together,
our data indicate that PIP5K1C generates at least half of all PIP2 in the DRG, including in
small-to-medium diameter, presumably nociceptive, DRG neurons. Moreover, our data
indicate that PIP2 is reduced in DRG of Pip5k1c+/− adult mice, but is not reduced in other
regions of the nervous system that process pain and somatosensory stimuli, including spinal
cord and brain.
Pip5k1c haploinsufficiency attenuates pronociceptive receptor signaling
Diverse molecules cause pain by activating pronociceptive G protein-coupled receptors
(GPCRs) in DRG neurons. Since PIP2 levels in the membrane were reduced by ~50% in
DRG neurons, we hypothesized that pronociceptive GPCRs that couple to phospholipases
and PIP2 hydrolysis would signal less effectively in Pip5k1c+/− mice. To test this hypothesis
we used the ratiometric calcium (Ca2+) indicator dye Fura-2-AM to quantify
lysophosphatidic acid (LPA) and 17-phenyl trinor prostaglandin E2 (17-PT PGE2) evoked
calcium responses in small-to-medium diameter DRG neurons. LPA evokes Ca2+ influx in
small-to-medium diameter DRG neurons and, when injected intrathecally (i.t.), produces a
chemically-induced form of neuropathic pain that is dependent on LPA1 receptor activation
(Elmes et al., 2004; Inoue et al., 2004). 17-PT PGE2 is a selective agonist for Gq-coupled
prostanoid receptors, a class of receptors that are implicated in pain hypersensitivity
following inflammation (Kassuya et al., 2007; Minami et al., 1994). Following stimulation
with LPA- or 17-PT PGE2, calcium responses (quantified as area under the curve; AUC)
were blunted in Pip5k1c+/− neurons compared to WT controls (Figure 2A–2D). Importantly,
these signaling deficits could be restored to WT levels by delivering excess PIP2 to
Pip5k1c+/− neurons just prior to imaging (Figure 2A–2D). These data suggest that the
signaling deficits observed in Pip5k1c+/− neurons were the result of reduced PIP2 levels and
were not due to poor cell health or PIP2- independent signaling deficits. Moreover, KCl-
evoked Ca2+ responses, which reflect activation of voltage-gated calcium channels, were not
altered (Figure 2A, data not shown). The percentage of neurons responding to either ligand
(LPA responders: mean 22.2 ± 2.9% for WT and 24.1 ± 3.7% for Pip5k1c+/−; 17-PT PGE2
responders: 6.0 ± 1.2% for WT and 4.7 ± 1.1% for Pip5k1c+/−) and the average diameter of
responding neurons was not significantly different between WT and Pip5k1c+/− cultures
(data not shown). We also found that delivering excess PIP2 to WT neurons did not elevate
LPAor 17-PT PGE2-evoked calcium responses beyond control levels, suggesting that PIP2
levels are already saturated in WT neurons under our culture conditions. Collectively, our
data reveal that PIP5K1C regulates signaling downstream from two pronociceptive
receptors, one associated with neuropathic pain and the other with inflammatory pain.
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Moreover, rescue experiments revealed that Pip5k1c regulates calcium signaling in DRG
neurons via a PIP2-dependent mechanism, placing PIP5K1C upstream of multiple signaling
pathways implicated in pain sensitization (Figure 2E).
Pip5k1c haploinsufficiency reduces ligand-induced nocifensive behaviors
LPA and 17-PT PGE2 induce GPCR-mediated nociceptive responses when injected into the
hindpaw (Kassuya et al., 2007; Renback et al., 1999; Renback et al., 2000). To determine if
these compounds signal less effectively in Pip5k1c+/− mice, we injected LPA (4.1 μg) or 17-
PT PGE2 (1.2 μg) into one hindpaw then monitored the duration of licking for 5 minutes.
We found that Pip5k1c+/− mice spent less time licking their ligand-injected hindpaws when
compared to WT littermates (Figure 2F). Reduced licking was not due to motor impairment,
as there were no significant differences between WT and Pip5k1c+/− mice in the rotarod
assay and gait was not impaired (stride or stance; Figure S2A–S2C). Moreover, acute
responses to innocuous mechanical touch were not impaired in Pip5k1c+/− mice (Figure
S2D).
There was also no loss of nociceptive neurons or terminals in spinal cord of Pip5k1c+/−
mice (determined by immunostaining for CGRP and IB4-binding, markers of nociceptive
neurons; Figure S3A-3J). And, excitatory synaptic transmission between sensory neurons
and spinal dorsal horn neurons was not impaired in Pip5k1c+/− mice, assessed by measuring
excitatory field potential (fEPSP) amplitude in spinal cord slices after stimulating the dorsal
root with a suction electrode (Street et al., 2011). Specifically, we found no significant
differences between genotypes in fEPSP amplitude at different stimulus strengths (Figure
S3K), following synaptic depletion (Figure S3L and S3M) or during synaptic recovery
(Figure S3N). These data also ruled out the possibility that synaptic transmission or synaptic
vesicle trafficking was impaired in Pip5k1c+/− mice. Instead, our data suggest that reduced
nocifensive licking in Pip5k1c+/− reflects reduced pronociceptive receptor activation in
vivo.
Pip5k1c haploinsufficiency attenuates TRPV1 activation and sensitization
PIP2 levels also affect the activity and sensitization of the capsaicin and noxious heat
receptor TRPV1 (Lukacs et al., 2007; Rohacs et al., 2008). To determine if Pip5k1c
haploinsufficiency affected TRPV1 activation, we stimulated cultured DRG neurons from
WT and Pip5k1c+/− mice with a high concentration of capsaicin (1 μM) then monitored
calcium responses. We found that capsaicin-evoked calcium responses were blunted in DRG
neurons from Pip5k1c+/− mice (Figure 3A) and that addition of exogenous PIP2 to
Pip5k1c+/− neurons restored capsaicin-evoked calcium responses to WT levels (Figure 3A
and 3B). These data are consistent with the literature showing that PIP2 is required for full
activity when TRPV1 is activated with a high concentration of capsaicin (Lukacs et al.,
2007; Rohacs et al., 2008). To evaluate TRPV1 sensitization by a GPCR agonist, we
stimulated DRG neurons with a submaximal capsaicin concentration (100 nM; to limit the
effects of Ca2+-induced desensitization), applied the GPCR agonist LPA (1 μM), and then
stimulated with capsaicin again to assess TRPV1 activity. We found that LPA sensitized
TRPV1 activity in neurons cultured from WT mice (AUC value increased from 6.3 ± 1.5 to
8.9 ± 1.5; unpaired t-test, p<0.05) (Figure 3C). In contrast, LPA failed to sensitize TRPV1 in
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neurons cultured from Pip5k1c+/− mice (AUC value decreased from 8.8 ± 2.0 to 3.6 ± 0.7;
suggesting TRPV1 was desensitized) (Figure 3C). This likely reflected normal
desensitization of TRPV1 caused by repeated capsaicin pulses (Loo et al., 2012). Consistent
with this possibility, we found that repeated application of capsaicin (without adding LPA)
caused desensitization of TRPV1 (data not shown). There was no significant difference in
AUC values between WT and Pip5k1c+/− neurons following the first application of this low
(100 nM) dose of capsaicin, consistent with previous literature showing that TRPV1 activity
is less affected by changes in PIP2 levels at low capsaicin concentrations (Lukacs et al.,
2007; Rohacs et al., 2008).
Next, we evaluated how Pip5k1c haploinsufficiency affected TRPV1-mediated nociception
in vivo. Injection of capsaicin (intraplantar) produced mechanical allodynia in WT mice but
not thermal hyperalgesia (Figure 3D, data not shown), consistent with a previous study
(Gilchrist et al., 1996). However, capsaicin-induced mechanical allodynia was significantly
blunted in Pip5k1c+/− mice (Figure 3D). Pip5k1c+/− mice also exhibited increased
withdrawal latencies at 45°C, 50°C, and 55°C relative to WT mice in the restrained hot plate
assay (Figure 3E). Taken together, these data suggest that Pip5k1c is required for
appropriate activation and sensitization of TRPV1 and for normal responsiveness to noxious
heat.
Pip5k1c haploinsufficiency impairs thermal and mechanical sensitization in models of
chronic pain
Pronociceptive receptor activation can sensitize animals to noxious thermal and mechanical
stimuli. Since pronociceptive receptors signaled less effectively in vitro and in vivo, we
hypothesized that thermal and mechanical sensitization might be blunted in Pip5k1c+/− mice
following inflammation or injury. Indeed, thermal hyperalgesia and mechanical allodynia
were enduringly attenuated in Pip5k1c+/− mice in models of chemically induced
neuropathic pain (i.t. injection of 1 nmol LPA), neuropathic pain caused by spared-nerve
ligation and inflammatory pain following an intraplantar injection of complete Freund’s
adjuvant (CFA) (Figure 4A–4F). There were no significant differences in the contralateral
(non-inflamed/non-injured) paw between WT and Pip5k1c+/− mice, and there were no
significant differences in either paw at baseline (prior to LPA injection, nerve injury, or
inflammation). Taken together, these data suggest that Pip5k1c regulates nociceptive
sensitization in three different models of chronic pain, with initiating events at three
different anatomical locations (intrathecal, peripheral nerves and hindpaw).
Identification of a small molecule PIP5K1C inhibitor that reduces membrane PIP2 levels
and reduces pronociceptive receptor signaling
At the time we began our research, there were no small molecule inhibitors of PIP5K1C or
any other lipid kinase that directly generates PIP2. Since small molecule inhibitors can
provide a complimentary method to validate targets when compared to genetic methods and
can establish target tractability for drug discovery efforts (Weiss et al., 2007), we set out to
identify a selective small molecule inhibitor of PIP5K1C. Accordingly, we developed a
high-throughput microfluidic mobility shift assay that separates fluorescein conjugated
PI(4)P (substrate) from fluorescein conjugated PIP2 (product) (Figure 5A and 5B). We used
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this assay to screen a kinase-focused library (~5,000 compounds) for inhibitors of
recombinant human PIP5K1C (data not shown, assay development and screen will be
described in a subsequent paper. Human and mouse PIP5K1C are 96% identical at the
amino acid level within the kinase domain and 92% identical across the entire protein).
From this screen, we identified UNC3230 [5- (cyclohexanecarboxamido)-2-
(phenylamino)thiazole-4-carboxamide] which had an IC50 of ~41 nM using the microfluidic
mobility shift assay (Figure 5C). To assess selectivity, we screened UNC3230 against 148
kinases (see Experimental Procedures), covering all major branches of the kinome (Figure
5D). Remarkably, UNC3230 inhibited (ProfilerPro assays) or competitively interacted
(DiscoveRX binding assays) with only five other kinases at our relatively high (10 μM)
screening concentration (using 10% activity/binding remaining relative to control as the
cutoff for each kinase group, except lipid kinases, where a more stringent 35% of control
cutoff was used) (Figure 5D, Table 1). Notably, UNC3230 did not interact with PIP5K1A at
10 μM, a PIP5K family member that is highly similar (69% amino acid identity across the
entire protein and 82% identity within the kinase catalytic domain) to PIP5K1C. And, based
on dose-responses with the five kinases that were inhibited by UNC3230 at the 10 μM
screening concentration, UNC3230 showed selectivity (Kd<0.2 μM; using competitive
binding assays) for PIP5K1C and PIP4K2C (Phosphatidylinositol-5-phosphate 4-kinase,
type II, gamma) (Figure 5E–5G). PIP5K1C and PIP4K2C directly generate PIP2, albeit
using different substrates; PI(4)P versus PI(5)P, respectively (Figure S4). UNC3230
represents the first reported inhibitor for these lipid kinases. Moreover, UNC3230 did not
inhibit any of the other lipid kinases that regulate phosphoinositide levels, including
phosphatidylinositol-4,5-bisphosphate 3-kinases (PIK3s, also known as PI3Ks) (Table 1,
Figure S4). Note, PIP4K2C should not be confused with phosphatidylinositol 4-kinases
(PI4Ks). PI4Ks generate PI(4)P from phosphatidylinositol and can be inhibited by
wortmannin and phenylarsine oxide (PAO; Figure S4) (Sorensen et al., 1998).
Inhibition of PIP5K1C and/or PIP4K2C would be predicted to reduce PIP2 levels, so we
assessed how UNC3230 affected PIP2 levels in DRG neurons by using the PIP2- specific
antibody. We found that membrane PIP2 levels were significantly reduced by ~45% in DRG
neurons treated with 100 nM UNC3230 (~2-fold above the IC50) relative to vehicle controls
(Figure 6A and 6B). PI(4)P is present at 10-fold higher concentration over PI(5)P in cells
(Delage et al., 2013), making UNC3230 more likely to affect PIP2 that is generated by
PIP5K1C. In addition, we found that UNC3230 significantly reduced LPA-evoked calcium
signaling in cultured DRG neurons relative to vehicle (Figure 6C and 6D). Collectively, our
data indicate that UNC3230 represents a novel pharmacological probe that can be used to
inhibit two lipid kinases that directly generate PIP2. Moreover, our data suggest that
UNC3230 blunts pronociceptive receptor signaling in DRG neurons in a manner that is
analogous to Pip5k1c haploinsufficiency.
UNC3230 has antinociceptive effects when injected intrathecally or into an inflamed
hindpaw
Next we monitored sensitivity in WT mice before and shortly after i.t. or intraperitoneal
(i.p.) administration of UNC3230. We found that UNC3230 (2 nmol in 20%
dimethylsulfoxide; DMSO) significantly increased noxious heat-evoked paw withdrawal
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latency for two hours after i.t. injection (Figure 7A), indicating an antinociceptive effect.
UNC3230 did not have an acute effect on mechanical sensitivity (Figure 7B) and did not
exhibit antinociceptive activity when administered i.p. (Figure S5A). This lack of activity
via the i.p. route could reflect different pharmacokinetic properties following systemic
versus localized (i.t. or into hindpaw, see below) drug delivery. To evaluate
dosedependence, we administered UNC3230 at 1, 2, and 3 nmol (i.t.). We did not observe
antinociceptive activity at 1 nmol (in 20% DMSO) but observed antinociceptive activity at 2
nmol (in 20% DMSO) that was similar to 3 nmol (in 50% DMSO) (Figure 7A and data not
shown). In contrast, an inactive analog that is structurally similar to UNC3230 (by addition
of a methyl group to the primary amide) did not exhibit thermal antinociceptive activity
(Figure S5B), suggesting the antinociceptive activity of UNC3230 reflects on-target
engagement of PIP5K1C (Figure S5B). Lastly, UNC3230 (2 nmol, i.t.) did not affect
performance in the rotarod assay (Figure S5C).
Given that UNC3230 blunted LPA-evoked signaling, and that LPA enduringly enhances
thermal and mechanical sensitivity by activating LPA receptors over a brief three hour
critical period (Ma et al., 2009), we next evaluated the extent to which UNC3230 could
reduce LPA-evoked thermal and mechanical hypersensitivity. We administered UNC3230
(2 nmol; i.t.; versus vehicle) then one hour later co-injected 1 nmol LPA with UNC3230 (2
nmol, i.t.; versus vehicle). UNC3230 significantly blunted thermal hyperalgesia and
mechanical allodynia compared to vehicle (Figure 7C and 7D). Next, we administered
UNC3230 (2 nmol; i.t.) two hours before and two hours after injecting CFA into one
hindpaw. We found that UNC3230 significantly blunted thermal hyperalgesia and
mechanical allodynia in the CFA-inflamed hindpaw (relative to vehicle control) but did not
affect thermal or mechanical sensitivity in the control (non-inflamed) hindpaw over a
multiday time course (Figure 7E and 7F). To determine if UNC3230 had antinociceptive
effects in animals with ongoing inflammation, we injected CFA into one hindpaw and then
48 h later injected UNC3230 (2 nmol; i.t.). UNC3230 significantly reduced existing CFA-
induced thermal hyperalgesia (relative to vehicle control) (Figure 7G). UNC3230 did not
affect existing mechanical allodynia when administered following CFA inflammation (data
not shown). Additionally, peripheral administration of UNC3230 (8 nmol, into the CFA-
inflamed hindpaw), reduced thermal hyperalgesia (Figure 7H). Taken together, these data
suggest UNC3230 could be used to block the initiation of chronic pain, with effects on
hypersensitivity that are similar in magnitude to Pip5k1c haploinsufficiency, and can reduce
established pain hypersensitivity.
DISCUSSION
Our study provides the first evidence that PIP5K1C generates at least half of all PIP2 in
DRG neurons and is a critical regulator of nociceptive signaling and sensitization, including
thermal and mechanical hypersensitivity in models of neuropathic and inflammatory pain,
two common forms of chronic pain in humans. Our conclusions are supported by
experiments with Pip5k1c+/− mice and with a small molecule inhibitor of PIP5K1C.
Pip5k1c haploinsufficiency reduced PIP2 levels in adult DRG by ~50% without affecting
PIP2 levels in adult brain or spinal cord (Figure 1K), making it unlikely that the phenotypes
we observed were due to Pip5k1c haploinsufficiency in other regions of the nervous system.
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Moreover, spinal delivery of UNC3230 recapitulated these antinociceptive phenotypes,
suggesting that localized inhibition of PIP5K1C in adults (and not during development) is
sufficient to reduce nociceptive sensitization.
With the possible exceptions of our intrathecal LPA experiment and intraplantar experiment
(Figure 4A,B and Figure 7H), in no cases was sensitization restored to baseline levels in
Pip5k1c+/− mice or following UNC3230 administration. This could reflect the fact that
GPCR signaling was reduced, but not eliminated, in neurons from Pip5k1c+/− mice and
following UNC3230 treatment. Moreover, there are likely additional enzymes in DRG that
generate PIP2 and contribute to pronociceptive receptor signaling. In support of this
possibility, PIP2 levels were not reduced to zero in DRG from Pip5k1c−/− (embryonic) mice
(Figure 1H). There are additional signaling pathways and cellular mechanisms that
contribute to nociceptive sensitization (Basbaum et al., 2009; Gold and Gebhart, 2010) and
some of these mechanisms are likely to be independent of Pip5k1c and PIP2.
Intrathecal injections target DRG and spinal cord (Luo et al., 2005). Our efforts to measure
small and possibly localized changes in PIP2 levels in DRG following intrathecal injection
were unsuccessful (data not shown). Thus, we cannot rule out the possibility that UNC3230
affects nociceptive sensitization by inhibiting PIP5K1C in the DRG and/or spinal cord
(PIP5K1C is expressed by spinal neurons but is not expressed by spinal microglial cells;
Allen Brain Atlas and data not shown). However, given that UNC3230 had antinociceptive
effects when injected intrathecally as well as peripherally into the hindpaw, our data
suggests that central or peripheral inhibition of PIP5K1C, presumably in primary sensory
neurons or their afferents, is sufficient to reduce nociceptive responses. Moreover, PIP2
levels were reduced in DRG but not spinal cord or brain of Pip5k1c+/− mice, suggesting the
antinociceptive phenotypes in Pip5k1c+/− mice were due to reduced activity of PIP5K1C in
primary sensory neurons.
As for why PIP2 levels were reduced in DRG of Pip5k1c+/− mice but not spinal cord or
brain, we speculate this reflects a greater dependence on Pip5k1c in DRG relative to these
other tissues. In support of this idea, PIP2 levels were not reduced in the brain of Pip5k1c+/−
mice (Figure 1K) (Volpicelli-Daley et al., 2010), but were reduced by 50% in the brain of
embryonic Pip5k1c−/− mice (Volpicelli-Daley et al., 2010; Wang et al., 2007). Thus, PIP2
levels in the central nervous system appear to be insensitive to Pip5k1c haploinsufficiency.
Additionally, PIP2 levels were not reduced in the brain of embryonic Pip5k1a, Pip5k1b
double knockout mice, suggesting other enzymes besides Pip5k1a, Pip5k1b, or Pip5k1c
generate PIP2 in the nervous system (Volpicelli-Daley et al., 2010). This greater dependence
on Pip5k1c in DRG makes this lipid kinase a particularly attractive target for analgesic drug
development, as inhibition of PIP5K1C has the potential to lower PIP2 levels in primary
sensory neurons to a greater extent than in the brain.
PIP5K1C modulates pronociceptive receptor signaling via a PIP2-dependent mechanism
PIP2-dependence was supported by the fact that addition of PIP2 rescued signaling deficits
in Pip5k1c+/− neurons. Others similarly found that PIP2 addition rescued histamine-evoked
calcium responses in HeLa cells following Pip5k1c knockdown (Wang et al., 2004). And,
ATP-evoked calcium release from purinergic receptors was significantly blunted in
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Pip5k1c+/− lateral nonsensory cells (Rodriguez et al., 2012), further indicating that Pip5k1c
regulates receptor signaling. Furthermore, our data reveals that Pip5k1c haploinsufficiency
eliminates GPCR-mediated sensitization of TRPV1 (Figure 3C).
Pip5k1c regulates many additional processes downstream of PIP2, including actin dynamics,
synaptic vesicle release and NMDA-induced AMPA receptor endocytosis (Rusinova et al.,
2013; Toth et al., 2012; Unoki et al., 2012; van den Bout and Divecha, 2009). We ruled out
the possibility that neurotransmission was impaired between sensory neurons and spinal
neurons in Pip5k1c+/− mice, making it unlikely that vesicle recycling deficits accounted for
reduced behavioral sensitization. However, we cannot exclude the possibility that other
mechanisms downstream of PIP2 are impaired in Pip5k1c+/− mice. Future studies will be
needed to assess the relative contribution of these downstream mechanisms to nociceptive
deficits in Pip5k1c+/− mice.
PIP5K1C is a novel analgesic drug target
The antinociceptive phenotypes in Pip5k1c+/− mice motivated us to develop a high-
throughput screen for PIP5K1C inhibitors. From this screen, we identified UNC3230, a
compound that inhibited PIP5K1C in the nanomolar range and that reduced receptor
signaling and nociceptive sensitization analogous to Pip5k1c haploinsufficiency. While we
evaluated the specificity of UNC3230 relative to a large panel of kinases, we cannot exclude
the possibility that UNC3230 inhibits kinases that were not available for testing, including
additional kinases that generate PIP2. Given that UNC3230 reduced PIP2 levels in DRG and
had antinociceptive activity in vivo, whereas an inactive close analog of UNC3230 did not
have antinociceptive activity, these data suggest that UNC3230 has on-target biochemical
effects. UNC3230 showed selectivity for PIP5K1C and PIP4K2C, two lipid kinases that
directly generate PIP2. The DiscoveRx Selectivity Profile score for UNC3230 was 0.12 (on
a scale from 0 to 1.0) (Karaman et al., 2008). To put this value in context, of 38 kinase
inhibitors (several of them FDA-approved) benchmarked in this assay at 3 μM (Karaman et
al., 2008), a majority (n=22) were less selective than UNC3230.
Our genetic and pharmacological data validate PIP5K1C as a therapeutic target for chronic
pain; however, further optimization of hits from our high-throughput screen is warranted.
For example, UNC3230 has a narrow efficacy window and low solubility in appropriate
vehicles that limited our ability to perform dose-responses in vitro and in vivo. These
shortcomings may be overcome through subsequent medicinal chemistry optimization,
particularly given that PIP5K1C inhibitors could provide an alternative to opioid and non-
steroidal anti-inflammatory analgesics. Moreover, PIP5K1C inhibitors will likely have uses
that extend beyond the nociceptive system, such as to study how transient PIP5K1C
inhibition affects other processes linked to PIP5K1C.
There are a number of additional enzymes that could affect PIP2 levels in DRG neurons,
including lipid kinases other than PIP5K1C, phosphatases and lipid transporters. Our current
study suggests these additional enzymes represent attractive targets for analgesic drug
development. In support of this idea, a functional-genomics study in Drosophila identified
phospholipid signaling and lipid kinases as key regulators of heat nociception (Neely et al.,
2012). This study also found that Pip5k1a−/− mice (not Pip5k1c) displayed hypersensitivity
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to noxious heat and capsaicin. However, given that Pip5k1a is expressed at much lower
levels in DRG (Figure 1A) and does not contribute to PIP2 levels in the central nervous
system (Volpicelli-Daley et al., 2010), precisely how and where Pip5k1a regulates heat
nociception in mice is unclear.
Human implications
Humans carrying heterozygous null mutations in Pip5k1c (i.e. PIP5K1C+/− humans)
develop normally and appear healthy (Narkis et al., 2007). Since humans apparently can
tolerate a life-long reduction in PIP5K1C gene dosage, drugs that transiently inhibit
PIP5K1C have the potential to be well-tolerated—particularly in adults—the age group that
suffers most from chronic pain. The high frequency hearing loss seen in Pip5k1c+/− mice is
not likely to be an issue in humans because humans cannot hear above 20 kHz (Brant and
Fozard, 1990). In contrast, PIP5K1C−/− humans develop lethal congenital contracture
syndrome type 3, which is characterized by muscle atrophy, joint contractures and death
within 24 hours of birth (Narkis et al., 2007). The human phenotype closely mimics the
perinatal lethality observed in the Pip5k1c−/− mice (Di Paolo et al., 2004). It is currently
unknown if PIP5K1C+/− humans have reduced pain responses, as we found with
Pip5k1c+/− mice. Future studies with these human carriers have the potential to directly
assess the importance of PIP5K1C in human pain perception.
Intriguingly, the individuals that carry the PIP5K1C mutation (PIP5K1C+/−) are Bedouins
and live in the Negev desert of Israel—an environment that is arid and subject to extreme
temperatures. Like sickle-cell anemia, where heterozygotes (carriers) have a survival
advantage in regions where malaria is endemic, mutations in PIP5K1C might provide a
survival advantage in the desert, where somatosensory stimuli can be extreme.
EXPERIMENTAL PROCEDURES
Animals
All procedures involving vertebrate animals were approved by the Institutional Animal Care
and Use Committee at the University of North Carolina at Chapel Hill. Pip5k1c+/− mice
were provided by Pietro De Camilli at Yale University (also available from The Jackson
Laboratory, #008515) (Di Paolo et al., 2004). All mice were backcrossed to C57BL/6 mice
for at least 10 generations.
Immunostaining
Lumbar DRG and spinal cord were dissected from adult (6–8 week old) male mice and
immunostained as previously described (McCoy et al., 2013; Zylka et al., 2008).
ELISA PIP2 quantification
PI(4,5)P2 mass ELISA was purchased from Echelon Biosciences (K-4500) and performed
according to the manufacturer’s instructions with the following alterations. Lumbar DRG
(L3-L5, bilateral), lumbar spinal cord and cerebral cortex were dissected from adult male
mice (6–8 weeks old) and all DRG were dissected from embryos (E17.5–18.5). All tissue
was frozen immediately on dry ice. Tissue was homogenized and sonicated prior to lipid
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extraction. DRG samples were diluted 1:40 and spinal cord and brain samples were diluted
1:200 prior to use in the ELISA assay. Bicinchoninic acid (BCA) protein determination
assay (ThermoScientific, 23225) was completed for each sample following the
manufacturer’s instructions. Protein content for each sample was used for normalization.
Neuron culture and calcium imaging
All DRG were dissected from 3–8 week old male mice following decapitation and cultured
as described (see Supplemental Experimental Procedures). Calcium imaging of dissociated
neurons was completed as described previously using Fura 2- acetoxymethyl ester (2 μM;
F1221, Invitrogen) (McCoy et al., 2013).
Behavioral assays
Pronociceptive ligands (4.1 μg LPA; 1.2 μg 17-PT PGE2, in 0.9% saline) were injected into
the left hindpaw and the amount of time spent licking was measured for 5 minutes. Thermal
and mechanical sensitivity were monitored before and 30 minutes after capsaicin (2 μg)
injection. Thermal sensitivity was measured using a Plantar Test apparatus (IITC) to heat
each hindpaw and the latency for hindpaw removal was recorded. One measurement was
taken for each hindpaw to determine the withdrawal latency in seconds. The radiant heat
source intensity was calibrated so that the average withdrawal latency for WT mice was ~10
s. Cut off time was 20 s. Mechanical sensitivity was measured using an electronic von Frey
apparatus (IITC) and a semi-flexible tip. Three measurements for each hindpaw were taken
and averaged to determine the withdrawal threshold in grams. For the restrained hot plate
test, animals were restrained by scruffing and the right hindpaw was placed on a metal
surface of the indicated noxious temperature. The latency for the animal to withdrawal (lift,
shake, or jump) its hindpaw was recorded. Inflammatory (CFA) and neuropathic (LPA and
spared nerve injury) models of chronic pain were performed as described previously (Ma et
al., 2009; Shields et al., 2003; Zylka et al., 2008). Intrathecal injections (5 μL) were
performed in unanesthetized mice using the direct lumbar puncture method (Fairbanks,
2003). UNC3230 was prepared at a final concentration of 0.4 mM (2 nmol per 5 μL) in 20%
DMSO or 0.6 mM in 50% DMSO for intrathecal injections. UNC3230 was prepared at a
final concentration of 0.4 mM in 20% DMSO for intraplantar injections (20 μL per hindpaw;
8 nmol total). For intraperitoneal injections, 5 mM UNC3230 was prepared in 90% corn oil
and 10% ethanol and administered at 20 mg/kg.
Small molecule inhibitor screen
N-terminal His6-tagged full length (90 kDa) recombinant human PIP5K1C (Millipore 14-
845) was incubated for 10 minutes in the presence or absence of small molecules in assay
buffer (50 mM MOPS, 500 μM sodium cholate, 10 mM magnesium chloride, and 25 mM
sodium chloride) in 384-well Nunc assay plates. Fluorescein conjugated substrate [PI(4)P;
Cayman Chemical, 9000655] and ATP at the Km concentration for PIP5K1C (15 μM) were
added to the assay plates and incubated for 40 minutes. Reactions were stopped using 90
mM EDTA. Fluorescein conjugated PIP2 and remaining PI(4)P were separated and
quantified using the LabChip EZ Reader II microfluidic mobility shift assay (PerkinElmer).
Validation of the assay was performed in duplicate using the library of pharmacologically
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active compounds (LOPAC; Sigma), giving a r2 value of 0.965. We used this assay to
screen a focused kinase library (~5,000 compounds), which contained UNC3230.
Selectivity screening
Two different assays were used to assess selectivity. ProfilerPro (PerkinElmer) was used to
assess selectivity of UNC3230 on 48 kinases. For the ProfilerPro assay, UNC3230 was
added to reaction-ready (384-well) assay plates (PerkinElmer) containing each of the 48
kinases in duplicate and incubated for 15 minutes. Matching fluorescent substrates for each
kinase (also provided in reaction-ready 384-well plates) and ATP at the Km for each kinase
were added then the plate was incubated for 90 minutes. Fluorescent substrates and products
were separated and quantified using the LabChip EZ Reader II microfluidic mobility-shift
assay (PerkinElmer). Data for this assay are reported as percent of control (product produced
in the absence of UNC3230).
The DiscoveRx KINOMEscan competitive binding assay was used to quantitatively
measure interactions between UNC3230 and 100 different kinases. Briefly, UNC3230 and
each DNA-tagged kinase were added simultaneously to 384-well plates containing
immobilized ligands for each of the 100 kinases tested. Plates were incubated for 1 hour and
the amount of kinase bound to the immobilized ligand was quantified using qPCR and the
associated DNA tag. Binding interactions were determined by the amount of kinase that
bound to the immobilized ligand. Competitive interactions between the kinase and
UNC3230 would prevent binding of the kinase to the immobilized ligand. Data for this
assay are reported as percent of control (binding of a control compound to the kinase).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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1. PIP5K1C generates PIP2 in somatosensory dorsal root ganglia neurons.
2. PIP5K1C regulates signaling through pronociceptive receptors.
3. Small molecule inhibitor of PIP5K1C identified.
4. Inhibition of PIP5K1C reduces sensitization in models of chronic pain.
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Figure 1. PIP5K1C is the predominant PIP2 synthesizing enzyme in embryonic and adult DRG
neurons
(A–C) In situ hybridization with gene-specific probes using sections from adult mouse
lumbar DRG. Scale bar, 50 μm. (D, E) Double fluorescence in situ hybridization using adult
lumbar DRG. Confocal images. Scale bar, 50 μm. (F, G) PIP5K1C protein levels in the
DRG of WT, Pip5k1c+/−, and Pip5k1c−/− embryonic (E17.5–18.5) mice relative to β-actin.
(F) Representative western blots using two different antibodies (top (Di Paolo et al., 2004),
bottom (Hara et al., 2013)) and (G) representative quantification for the Di Paolo et al.
antibody; n=2–3 embryos per genotype. (H) PIP2 levels in embryonic (E17.5–18.5) DRG
quantified by a competitive binding enzyme-linked immunosorbent assay (ELISA) from
WT, Pip5k1c+/−, and Pip5k1c−/−mice. n=10 embryos per genotype. (I, J) PIP5K1C protein
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levels in adult DRG. (I) Western blots and (J) quantification; n=3 per genotype. (K) PIP2
levels in DRG, spinal cord, and brain (cerebral cortex) of adult male Pip5k1c+/+ and
Pip5k1c+/− mice, quantified by ELISA. n=10 mice per genotype. (L) Representative images
of membrane PIP2 staining in small diameter DRG neurons cultured from Pip5k1c+/+ and
Pip5k1c+/− adult mice relative to NeuN and (M) quantification of the average perimeter
(membrane) intensity. n=28 small diameter neurons quantified per genotype. All data are
mean ± SEM. *p<0.05, ***p<0.0005. See also Figure S1.
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Figure 2. Pip5k1c haploinsufficiency reduces ligand-evoked nociceptive signaling in vitro and
nocifensive licking in vivo
(A,C) Calcium responses and (B,D) quantification. Cultured adult DRG neurons were
stimulated with (A, B) 10 μM LPA or (C, D) 10 μM 17-PT PGE2 for 90 s, washed with
HBSS for 120 s to remove the ligand, then stimulated for 30 s with 100 mM KCl to confirm
neuron identity (not shown for 17-PT PGE2). Cultures were incubated with 2 μM carrier or 2
μM Carrier + 2 μM PIP2 for 15 minutes prior to calcium imaging. Number of neurons
quantified is indicated in the bar graph. (E) Model. PIP5K1C generates PIP2 that is
hydrolyzed downstream of pronociceptive receptor activation. Ca2+ influx and PKC
activation contribute to nociceptive sensitization. Pip5k1c haploinsufficiency reduces the
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amount of PIP2 that is available for signaling in DRG neurons. (F) Time spent licking for
the first 5 minutes after injecting vehicle, 4.1 μg LPA, or 1.2 μg 17-PT PGE2 into the left
hindpaw of adult WT and Pip5k1c+/− male mice. n=10 per genotype per agonist. (A–D, F)
All data are mean ± SEM. *p<0.05, ***p<0.0005. See also Figures S2, S3.
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Figure 3. Pip5k1c haploinsufficiency reduces TRPV1-mediated nociceptive signaling in vitro and
in vivo
(A) Capsaicin-evoked calcium responses and (B) quantification of cultured adult DRG
neurons. Neurons were stimulated with 1 μM capsaicin for 90 s, washed with HBSS for 280
s, then stimulated for 30 s with 100 mM KCl to confirm neuron identity. Cultures were
incubated with 2 μM carrier or 2 μM Carrier + 2 μM PIP2 for 15 minutes prior to calcium
imaging. Number of neurons quantified is indicated in the bar graph. (C) Capsaicin-evoked
(Cap, grey, 100 nM) calcium responses before and after incubating with LPA. Average
traces for 156 WT neurons and 143 Pip5k1c+/− neurons. (D) Mechanical sensitivity before
and 30 minutes after intraplantar injection of 2 μg capsaicin. n=10 mice per genotype. (E)
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Restrained hotplate assay. n=30 mice per genotype. All data are mean ± SEM. *p<0.05,
**p<0.005, ***p<0.0005. See also Figure S3.
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Figure 4. Pip5k1c haploinsufficiency attenuates thermal and mechanical sensitization in models
of inflammatory pain and neuropathic pain
(A) Thermal (radiant heating; Hargreaves assay) and (B) mechanical (electronic von Frey)
sensitivity in LPA-induced neuropathic pain model. LPA (1 nmol in 0.9% saline, i.t.)
administered at the indicated time (arrow) to adult WT and Pip5k1c+/− mice. n=11 male
mice per genotype. (C) Thermal and (D) mechanical sensitivity in the spared nerve injury
model of neuropathic pain. Contralateral hindpaw served as a control. n=10 male mice per
genotype. (E) Thermal and (F) mechanical sensitivity in CFA inflammatory pain model.
CFA (20 μL) was injected into one hindpaw. Contralateral paw was not injected and served
as a control. n=10 male mice per genotype. (A–F) All data are mean ± SEM. Asterisks
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indicate significant difference between WT and Pip5k1c+/− mice by a one-way ANOVA.
*p<0.05, **p<0.005, ***p<0.0005.
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Figure 5. Identification of UNC3230 as a selective small molecule PIP5K1C inhibitor
(A) High-throughput screen is based on incubating fluorescein conjugated PI(4)P (substrate)
with recombinant human PIP5K1C and then measuring product formation using a
microfluidic mobility shift assay (LabChip). (B) Representative traces showing substrate and
product peak separation in assay performed with and without a small molecule inhibitor
(UNC3230; 10 μM). (C) UNC3230 structure and inhibitory concentration-50 (IC50) doses-
response curve, using LabChip assay. (D) Selectivity of UNC3230 relative to a diverse panel
of kinases, using ProfilerPro (48 kinases) and KINOMEscan (100 kinases) assays. Table 1
lists all kinases that were tested. Circle size and color reflects percent activity/binding
remaining in the presence of UNC3230 (10 μM) relative to controls. Branches without
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circles denote kinases that were not tested. AGC: Containing PKA, PKG, PKC families;
CAMK: Calcium/calmodulindependent protein kinase; CK1: Casein kinase 1; CMGC:
Containing CDK, MAPK, GSK3, CLK families; STE: Homologs of yeast Sterile 7, Sterile
11, Sterile 20 kinases; TK: Tyrosine kinase; TKL: Tyrosine kinase-like. Image generated
using TREEspot™ Software Tool and reprinted with permission from KINOMEscan®, a
division of DiscoveRx Corporation, © DISCOVERX CORPORATION 2010. (E–G)
KINOMEscan competitive binding assays with multiple doses of UNC3230, presented from
(E) strongest Kd to (G) weakest Kd. All data are mean ± SEM. See also Figure S4.
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Figure 6. UNC3230 reduces membrane PIP2 levels in DRG neurons and GPCR signaling
(A) PIP2 antibody staining of WT DRG neurons after incubating with vehicle (0.002%
DMSO) or 100 nM UNC3230 for 20 h. Co-stained with the neuronal marker NeuN (blue).
(B) Quantification of the average perimeter (membrane) intensity. n=30–40 neurons per
condition. (C) LPA-evoked calcium response in WT DRG neurons after incubating with
vehicle or the indicated concentrations of UNC3230 for 20 h. After stimulation, cultures
were washed with HBSS for 120 s to remove LPA, then stimulated for 30 s with 100 mM
KCl to confirm neuron identity. (D) Quantification of the LPA-evoked calcium response by
measuring the AUC of each responding neuron. Number of neurons quantified is indicated
in bar graph. Data are mean ± SEM. *p<0.005, ***p<0.005.
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Figure 7. UNC3230 reduces thermal and mechanical sensitization in models of chronic pain
(A) Thermal and (B) mechanical sensitivity of WT mice after administering vehicle or 2
nmol UNC3230 (i.t.). Arrow indicates injection. n=10 male mice per group. (C) Thermal
and (D) mechanical sensitivity of WT mice in the LPA-induced neuropathic pain model.
Vehicle or 2 nmol UNC3230 were administered i.t. One hour later, vehicle or 2 nmol
UNC3230 was administered i.t. with 1 nmol LPA. n=10 male mice per group. (E) Thermal
and (F) mechanical sensitivity of WT mice in the CFA model of inflammatory pain. Vehicle
or 2 nmol UNC3230 were administered i.t. Two hours later, CFA was injected into one
hindpaw of each animal. The other hindpaw was not inflamed and served as a control.
Vehicle or 2 nmol UNC3230 was administered (i.t.) 2 hours after CFA injection. n=10 male
mice per group. (G–H) Thermal sensitivity of WT mice in the CFA model of inflammatory
pain. CFA was injected into one hindpaw of each animal. The other hindpaw was not
inflamed and served as a control. (G) Two days post CFA injection, vehicle or 2 nmol
UNC3230 was administered i.t. n=10 male mice per group. (H) One day post CFA injection,
vehicle or 8 nmol UNC3230 was administered into the inflamed hindpaw. n=10 mice per
group. (A) One-way ANOVA with post hoc Bonferonni correction was used to compare
differences between treatment groups for the 5 hour time course and at each hour. Black
asterisks indicate significance at individual time points. ANOVA for the 5 hour time course,
p=0.0045. (C–H) One-way ANOVAs were used to assess treatment effect over the 7-day
time course (black asterisks). (G) One-way ANOVA was used to assess treatment effect in
the non-inflamed paw over the 5 hour time course following injection (grey asterisk). All
data are mean ± SEM. *p<0.05, **p<0.005. See also Figure S5.
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Table 1
List of kinases screened for UNC3230 selectivity with numbers representing %activity/binding remaining in



























































































































































































































Screened using the PerkinElmer ProfilerPro assay, all others screened using the DiscoveRx KINOMEscan assay.
Neuron. Author manuscript; available in PMC 2015 May 21.
